ELV Stock Forecast & Price Target

Elevance Health is supported by a durable franchise as the largest Blue Cross Blue Shield licensee across 14 states, with 45 million medical members and broad exposure across employer, individual, Medicaid, and Medicare Advantage products. Its outlook strengthens as 3Q26 beat expectations, FY26 adjusted EPS guidance rose to at least $29.00, operating cash flow was lifted to at least $6.5 billion, and management reiterated at least 12% EPS growth in 2027 off a higher baseline. Fundamental upside also comes from improving Medicaid margins, at least 2% Medicare Advantage operating margins with room to expand, stronger ACA retention, and Carelon’s growing contribution through pharmacy benefit management and healthcare services.

Elevance Health is facing a materially more uncertain earnings profile as regulatory and medical-cost pressures build across its core government and specialty businesses. The company has already recorded about $669 million of liabilities tied to No Surprises Act IDR matters, with another $324 million of unresolved exposures, while roughly 94% of the potential exposure is linked to ASO business and could remain vulnerable to ongoing regulatory and litigation developments. At the same time, Medicare Advantage reimbursement risk, Medicaid redetermination headwinds, weaker ACA risk pools, and PBM pressure on IngenioRx—about 20% of company earnings—support a cautious outlook even as management lowered target operating margins to 5.0%–6.0%.